Safety and tolerability study of sotrovimab (VIR-7831) prophylaxis against COVID-19 infection in immunocompromised individuals with impaired SARS-CoV-2 humoral immunity.
Saved in:
| Title: | Safety and tolerability study of sotrovimab (VIR-7831) prophylaxis against COVID-19 infection in immunocompromised individuals with impaired SARS-CoV-2 humoral immunity. |
|---|---|
| Authors: | Gonzalez-Bocco, Isabel H.1,2,3 (AUTHOR) Isabel_gonzalez-bocco@dfci.harvard.edu, Beluch, Katherine1,2 (AUTHOR), Cho, Alyssa1,2 (AUTHOR), Lahoud, Chloe1,2,3 (AUTHOR), Reyes, Fabiola A.1,2,3 (AUTHOR), Moshovitis, Dimitrios G.1,2 (AUTHOR), Unger-Mochrie, Gillian M.2 (AUTHOR), Wang, Wei3,4 (AUTHOR), Hammond, Sarah P.1,3,5 (AUTHOR), Manne-Goehler, Jennifer2,3,5 (AUTHOR), Koo, Sophia1,2,3 (AUTHOR) skoo@bwh.harvard.edu |
| Source: | Pilot & Feasibility Studies. 6/16/2023, Vol. 9 Issue 1, p1-10. 10p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
